Interstitial pneumonia and other adverse events in riluzole-administered amyotrophic lateral sclerosis patients: a retrospective observational study

Aya Inoue-Shibui, Masaaki Kato, Naoki Suzuki, Junpei Kobayashi, Yoshiki Takai, Rumiko Izumi, Yuuko Kawauchi, Hiroshi Kuroda, Hitoshi Warita and Masashi Aoki*

Abstract

Background: Riluzole is the only approved oral drug for amyotrophic lateral sclerosis (ALS). We performed a retrospective study including ALS patients treated with riluzole, focusing on adverse events.

Methods: Patients diagnosed with ALS according to the revised El Escorial criteria (World Federation of Neurology) in our center and who were administered 50 mg oral riluzole twice daily between January 2011 and September 2017 and followed up for at least 6 months from treatment initiation or until death were included. Data regarding sex, age, disease type, initial symptoms, biochemical analyses performed before and after riluzole administration, and medical history were collected. In case of withdrawal, cause of discontinuation and durations of disease and drug administration were recorded.

Results: A total of 92 cases were enrolled. Riluzole administration was discontinued in 20 cases (21.7%). The most frequent reason for discontinuation was elevated liver enzymes ($n = 5$, 5.4%), followed interstitial pneumonia (IP), nausea and appetite loss, dizziness, general malaise, tongue paresthesia, and urinary urgency. In two cases, administration was discontinued primarily because of progression of bulbar palsy. All adverse events occurred within 6 months from treatment initiation and improved soon after its discontinuation. Three IP cases developed severe respiratory failure and required steroid treatment.

Conclusion: Riluzole administration was discontinued in 20 cases among total of 92 cases. Careful follow-up is important for the first six months after the initiation of riluzole administration, including through interviews, chemical analyses, and chest X-rays, as required.

Keywords: Amyotrophic lateral sclerosis, Interstitial pneumonia, Riluzole, Liver dysfunction, Adverse events, Side-effect

Background

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease, primarily affecting upper and lower motor neurons. Glutamate excitotoxicity, which leads to neural damage, is one of the causative mechanisms [18]. Riluzole, the only approved oral drug for ALS, is a pre-synaptic glutamate release inhibitor, which may prevent neural damage and delay muscle-strength deterioration. Moreover, it decreases peak sodium (Na+) current and mediates voltage-gated Na+ channel inactivation, which inhibit persistent Na+ current in motor neurons, decreasing neuronal excitability and leading to neural protection [1, 18]. Although riluzole was well tolerated by and increased survival of ALS patients [4, 15], whether the survival benefit is elicited at the early or late stage or throughout the course of the disease remains controversial [7, 8, 14]. In terms of adverse events due to riluzole, few reports have focused on summative assessment [3, 4, 7, 8, 10, 15]. Effects of riluzole on the overall quality of life and disease progression remain to be established [19].

* Correspondence: aokim@med.tohoku.ac.jp
Department of Neurology, Tohoku University Graduate School of Medicine
Japan, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
of life (QOL) of patients remain unknown. To investigate potential adverse events during riluzole treatment and to establish strategies to prevent or manage such events, we performed a retrospective study of ALS patients treated with riluzole, focusing on cases of withdrawal.

Methods
The study was submitted to and approved by the Ethics Committee of Tohoku University Graduate School of Medicine (2010–253, 2017–1-005). Consent to participate was directly provided by patients or their families.

Patients diagnosed with ALS (clinically definite, clinically probable, clinically probable-laboratory supported, or clinically possible) according to the revised El Escorial criteria (World Federation of Neurology) in our center and who were administered 50 mg oral riluzole twice daily between January 2011 and September 2017 and followed up for at least 6 months from treatment initiation or until death were included. Data regarding sex, age, disease type, initial symptoms, biochemical analyses before and after riluzole administration, and medical events and histories were recorded. When alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were > 3× the upper limit of the normal level [2, 12] and accompanied by additional subjective symptoms, such as anorexia, nausea, or dizziness, liver dysfunction was considered and riluzole was discontinued. In addition, in cases of withdrawal, causes of discontinuation and durations of disease and drug administration were recorded. Wald chi-square and t-test were used for data analysis. \( P < 0.05 \) was considered significant.

Results
In total, 92 cases were followed up for a median of 15.5 months [interquartile range (IQR), 9–22 months]. Median patient age was 64.5 and 62.5 years in discontinuation and continuation cases, respectively \( (P = 0.35) \). The initial symptom was muscle weakness in almost all cases (discontinuation: 19/20; continuation: 70/72), and cervical area was the most common site of symptoms (discontinuation: 9/20; discontinuation: 23/72; \( P = 0.5 \)). Frequency of ALS/frontotemporal dementia was 20% (4/20) in the discontinuation cases \( (P = 0.77) \) and 12.5% (10/72) in the continuation cases. No patient characteristics were significantly associated with drug discontinuation (Table 1).

The most frequent cause of discontinuation was elevation of liver enzymes \( (n = 5/92, 5.4\%) \) followed by interstitial pneumonia (IP), nausea or appetite loss, dizziness, general malaise, tongue paresthesia, or urinary urgency. In two cases, the drug was discontinued because of progression of bulbar palsy. Median disease duration was 2 years (IQR, 1–3; range, 0–20). All adverse events occurred within 6 months of riluzole initiation, with half of the events occurring within 14 days (Tables 2 and 3). Median duration of drug administration in continuation cases was 15.5 months (IQR, 9–22 months), with the longest duration of 4 years (Data not shown).

In this study, ALS patients who showed ALT and AST levels > 3× of the upper limit of the normal level [2, 12] and accompanied by additional subjective symptoms, such as anorexia, nausea, or dizziness, liver dysfunction was considered and riluzole was discontinued. In addition, in cases of withdrawal, causes of discontinuation and durations of disease and drug administration were recorded. Wald chi-square and t-test were used for data analysis. \( P < 0.05 \) was considered significant.

Table 1 Profiles of the ALS cases examined in this study

|                  | Discontinued | Continued | \( P \) value |
|------------------|--------------|-----------|--------------|
| n                | 20           | 72        |              |
| Sex (male, n, %) | 12, 60       | 34, 47.2  | 0.31         |
| Age (Median, IQR, years old) | 64.5 (58.3–72.8) | 62.5 (56.5–69.3) | 0.35 |
| Initial symptom, n | Muscle weakness: 19 | Muscle weakness: 70 |              |
|                   | Muscle cramp: 1 | Muscle cramp: 1 |              |
| Onset site of weakness (n, %) | B: 5, 25.0 | B: 23, 31.9 | 0.4 |
|                   | C: 9, 45.0 | C: 23, 31.9 | 0.5 |
|                   | T: 0, 0 | T: 2, 28 | 0.5 |
|                   | L: 6, 30.0 | L: 22, 30.6 | 0.63 |
| FTD (n, %) | 5, 20 | 10, 12.5 | 0.77 |

\( B \) bulbar, \( C \) cervical, \( FTD \) Frontotemporal dementia, \( L \) lumbar, \( T \) thoracic, \( P \) values are obtained by the Wald chi-square test, based on the null hypothesis that the characteristic contributes to the discontinuation more than the other reasons in the discontinued group. \( P \) value of age is obtained by t-test, compared discontinued group with continued group.

No patient characteristics were significantly associated with drug discontinuation.
**Table 2** Characteristics of the discontinued cases

| No. | Sex | Onset Age, site | Dementia type | The reason of discontinuation of riluzole | Duration from the beginning of riluzole (days) | Duration of ALS at withdrawing riluzole (years) | Past histories |
|-----|-----|----------------|--------------|--------------------------------------------|-----------------------------------------------|-----------------------------------------------|----------------|
| 1   | M   | 60, L          | ALS          | Nausea                                     | 0–3                                          | 3                                             | BPH, Depressive status, HT |
| 2   | M   | 77, C          | ALS          | IP                                         | 60                                           | 1                                             | Past smoker, HT |
| 3   | F   | 75, B          | ALS          | Progression of bulbar palsy                |                                               | 3                                             | Diabetes       |
| 4   | F   | 64, C          | ALS/FTD      | Appetite loss                              | 0–3                                          | 5                                             |                             |
| 5   | M   | 77, C          | ALS/FTD      | Urinary urgency                            | 0–3                                          | 2                                             | OMI, Chronic gastritis |
| 6   | M   | 53, C          | ALS          | Progression of bulbar palsy                |                                               | 3                                             |                             |
| 7   | M   | 63, B          | ALS          | Refusal                                    | 90–120                                       | 20                                            | Ventricular aneurism, HT |
| 8   | M   | 75, L          | ALS          | Dizziness                                  |                                               | 1                                             | Emphysema, BA, HT, CAVB |
| 9   | F   | 72, B          | ALS/FTD      | IP                                         | 150                                          | 1                                             | HT, HL          |
| 10  | F   | 67, L          | ALS          | General malaise                            | 90                                           | 3                                             | none            |
| 11  | F   | 43, L          | ALS          | Chlamydia pneumonia s/o, IP n/r/o           | 14                                           | 4                                             | none            |
| 12  | M   | 53, L          | ALS          | Paresthesia of tongue                      | 180                                          | 1                                             | Psoriasis vulgaris |
| 13  | M   | 54, L          | ALS          | Elevated liver enzymes                     | 3                                            | 2                                             | Diabetes, HL    |
| 14  | M   | 56, B          | ALS          | Elevated liver enzymes / dizziness         | 14                                           | 1                                             | Reflux esophagitis, Heavy drinker |
| 15  | F   | 63, C          | ALS          | Dizziness                                  | 4                                            | 2                                             | none            |
| 16  | F   | 67, C          | ALS          | Elevated liver enzymes / General malaise   | 30                                           | 5                                             | HL              |
| 17  | F   | 78, B          | ALS/FTD      | Appetite loss                              | 9                                            | 1                                             | HT, HL, Depressive status |
| 18  | M   | 68, C          | ALS          | Elevated liver enzymes                     | 2–14                                         | 1                                             | Diabetes, HT    |
| 19  | M   | 65, C          | ALS          | Elevated liver enzymes / dizziness         | 0–14                                         | 1                                             | Diabetes, HL    |
| 20  | M   | 59, C          | ALS          | IP                                         | 60                                           | 2                                             | Past smoker, HT |

*BA bronchial asthma, BPH Benign prostatic hyperplasia, CAVB complete arterial-ventricular block, F: female, HT Hypertension, HL Hyperlipidemia, IP interstitial pneumonia, M male, N/R/O not ruled out, OMI old myocardial infarction, S/O suspected of +: having dementia, –: not having dementia

All cases with elevated liver enzymes that discontinued riluzole presented a history of medication for diabetes or hyperlipidemia

**Table 3** Characteristics of the discontinued cases, categorized into events

| The reason of discontinuation of riluzole | n (rate vs. all, %) | Sex (Male, %) | Onset of ALS Age (years old, median, IQR) | Duration from the beginning of riluzole (days, median, IQR) | Duration of ALS at withdrew riluzole (years, median, IQR) | Past histories (n) |
|-----------------------------------------|---------------------|---------------|-------------------------------------------|---------------------------------------------------------------|-----------------------------------------------------------|--------------------|
| Elevated liver enzymes                  | 5 (5.4)             | 80            | 65 (56–67)                                | 11 (7.3–14)                                                  | 1 (1–2)                                                   | Diabetes/HT/HL (4), Reflux esophagitis (1), Heavy drinker (1) |
| IP                                      | 4 (4.3)             | 50            | 65.5 (55–73.3)                            | 60 (48.5–82.5)                                               | 2 (1.8–2.5)                                               | past smoker (2)    |
| Appetite loss / Nausea                  | 3 (3.3)             | 33            | 64 (62–71)                                | 2 (2–5.5)                                                   | 3 (2–4)                                                   | Depressive status (2) |
| Dizziness                               | 2 (2.2)             | 50            | 69 (66–72)                                | 4 and 90–120, respectively                                   | 2 and 20 years, respectively                             |                    |
| General malaise                         | 1 (1.1)             | 0             | 67                                        | 90                                                          | 3                                                         |                    |
| Paresthesia of tongue                   | 1 (1.1)             | 100           | 53                                        | 180                                                         | 1                                                         | Psoriasis vulgaris |
| Urinary urgency                         | 1 (1.1)             | 100           | 70                                        | 0–3                                                         | 2                                                         |                    |

*The most frequent cause of discontinuation was elevation of liver enzymes (n = 5/92, 5.4%) followed by IP, nausea or appetite loss, dizziness, general malaise, tongue paresthesia, or urinary urgency. In two cases, the drug was discontinued because of progression of bulbar palsy. Median disease duration was 2 years (IQR, 1–3; range, 0–20). All adverse events occurred within 6 months of riluzole initiation, with half of the events occurring within 14 days*
with abnormal elevated enzymes presented with a medical history of diabetes, hyperlipidemia, or hypertension and received medication for these conditions (Table 2). Furthermore, in two cases with elevated liver enzymes, biochemical analyses before riluzole administration showed moderately elevated γ-GTP levels (Tables 2 and 3). Two continuation cases showed slightly elevated liver enzyme levels. Overall, 8 of the 72 continuation cases showed mildly elevated liver enzyme levels (< 70 U/L) after drug administration, but there were no accompanying symptoms.

Adverse events improved soon after drug discontinuation, except in three cases of IP that required steroid treatment to achieve a good response. Two cases with elevated liver enzymes and severe IP are reported below.

**Case 1**
The patient complained of weakness in her left (Lt.) upper limb at the age of 68 years, which gradually spread to the other side. Moreover, she experienced cramps in her Lt. upper and lower limbs at the age of 70 years and was admitted to our hospital. She presented no relevant family history. She presented a medical history of hyperlipidemia and received medication for it. Neurological examination revealed moderate muscle atrophy and weakness in her Lt. upper and lower limbs and fasciculation in her upper limbs. Electromyography revealed fasciculation in the thoracic area. We diagnosed the patient with ALS and initiated treatment with 50 mg riluzole twice daily. After 2 weeks of riluzole initiation, a skin rash appeared and riluzole was withdrawn. Riluzole was resumed 3 weeks after day 1 of treatment. Then, she complained of general malaise. Biochemical analysis at day 30 of riluzole treatment revealed elevated AST from 21 to 50 U/L and elevated ALT from 25 to 88 U/L (Table 4). We suspected drug-induced hepatic injury and discontinued the medication. Her liver enzyme levels worsened at 1 month after drug discontinuation but gradually improved; the symptom disappeared within 2 months after riluzole discontinuation (Table 4).

**Case 2**
The patient complained of fasciculation and muscle weakness in his upper limbs at the age of 59 years and was admitted to our hospital at the age of 60 years. He presented no relevant family history. He presented a medical history of proton pump inhibitor use. He was a past smoker of 30 cigarettes per day for 25 years. Neurological examination revealed hypertonus in his four extremities and muscle atrophy and weakness in his upper limbs. Electromyography revealed active denervation potentials in the cervical, thoracic, and lumbar areas. We diagnosed the patient with ALS and initiated treatment with 50 mg riluzole twice daily. The patient complained of shortness of breath and dry cough 2 months after treatment initiation. Physical examination revealed blood pressure of 105/75 mmHg and heart rate of 77 beats per minute. His SpO2 in room air was 92%. Routine biochemical analyses revealed increased KL-6 (1151 U/mL), SP-D (414 ng/mL), lactate dehydrogenase (354 U/L), C-reactive protein (0.9 mg/dL), and serum amyloid A (68.8 µg/mL) levels. Arterial blood gas analysis revealed hypoxemia with pO2 of 68.2 mmHg (Table 5). Chest X-ray and computed tomography (CT) revealed consolidation in the bilateral lower lung lobes (Fig. 1a). Pulmonary function test revealed diffusion impairment, with percent vital capacity (%VC) of 79.8%, forced expiratory volume percent in one second (FEV1.0%) of 70.4%, and diffusing capacity of the lung carbon monoxide (DLCO) of 49.2%. Drug-induced pneumonia was suspected, and riluzole treatment was withdrawn at day 80 of riluzole initiation. Bronchoalveolar lavage showed 57.8% increase in the lymphocyte counts. Transbronchial lung biopsy was performed from the right upper and lower segmental bronchi. Pathological analysis revealed organizing pneumonia—a subtype of IP. As the clinical course was acute and different from that of food microaspiration-induced idiopathic pulmonary fibrosis [19], we diagnosed the patient with drug-induced IP, and initiated oral prednisolone at 0.5 mg/kg body weight per day. Immediately, the symptoms and respiratory failure improved, with DLCO increasing to 105.3% and consolidation disappearing in 30 days (Table 5, Fig. 1b).

**Discussion and conclusion**
Riluzole is a presynaptic glutamate release inhibitor, which protects motor neuron from toxic neural excitation. The most common adverse events due to riluzole is elevated liver enzyme levels, specifically ALT (6.9%), AST (6.6%), and γ-GTP (3.8%), as well as nausea (3.8%), according to a treatment outcome study in the pharmaceutical reference. In a previous study, ALT levels

### Table 4 The course of biochemical analyses data of case 1 with elevated liver enzymes

|                     | AST | ALT | ALP | γ-GTP | LDH | T-Bil |
|---------------------|-----|-----|-----|-------|-----|-------|
| Before riluzole treatment | 21  | 25  | 189 | 15    | 187 | 0.8   |
| When abnormality occurred | 50  | 88  | 259 | 17    | 213 | 0.7   |
| The worst biochemical data | 65  | 132 | 238 | 37    | 229 | 0.8   |
| After discontinuation  | 25  | 37  | 259 | 21    | 175 | 0.6   |

ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, γ-GTP gamma-glutamyl transpeptidase, T-Bil total bilirubin T-bil: mg/dL, Others: U/L

Biochemical analysis at day 30 of riluzole treatment revealed elevated AST from 21 to 50 U/L and elevated ALT from 25 to 88 U/L. The liver enzyme levels worsened at 1 month after drug discontinuation but gradually improved; the symptom disappeared within 2 months after riluzole discontinuation.
Table 5 The course of biochemical analyses and pulmonary function data of our IP case

| Biochemical analysis | LDH | CRP | SAA | KL-6 |
|----------------------|-----|-----|-----|------|
| onset                | 354 | 0.9 | 68.8| 1152 |
| after treatment      | 272 | 0.1 | 7.3 | 469  |
| Blood gas analysis   | pH  | pCO₂| pO₂ | HCO₃ |
| onset                | 7.41| 36.9| 66.2| 22.3 |
| Pulmonary function test | % VC | FEV₁.0% | DLCO |
| onset                | 79.8| 70.4| 49.2|
| after treatment      | 95.9| 73.3| 105.3|

CRP C-reactive protein, mg/dL, DLCO Diffusing capacity of the lung carbon monoxide, ml/min/mmHg, FEV₁.0% Forced expiratory volume percent in one second, %, KL-6 Krebs von den Lungen-6, U/mL, LDH lactate dehydrogenase, U/L, pCO₂: mmHg, pO₂: mmHg, SAA Serum amyloid A, mg/mL, SP-D surfactant proteins D, ng/mL, %VC Percent vital capacity, %.

On his admission, routine biochemical analyses revealed increased levels related to IP. Arterial blood gas analysis revealed hypoxemia. Pulmonary function test revealed diffusion impairment. The symptoms and respiratory failure improved, with DLCO increasing after discontinuation and steroid treatment.

elevated 2–4 times the normal range in 7.8% of the cases and AST levels elevated 4 times the normal range in 14.2% of the cases were reported, with 6.5% of the cases showing elevation of both enzymes; 6.5% cases resulted in drug withdrawal in that study, and enzyme levels returned to normal within 2 months after riluzole discontinuation [4]. Another study reported elevated ALT in 6.7% cases and elevated AST in 3.8% cases [15]. In addition to liver enzyme levels, asthenia prevalence of 8.5% (versus 7.0% in placebo) and nausea prevalence of 4.9% (versus 3.5% in placebo) has been reported [3]. All adverse events, except for urinary urgency, noted in this study have been reported in previous research studies or pharmaceutical references (Table 3). All five cases with elevated liver enzyme (5.4%) showed elevated ALT and AST levels, whereas only two cases showed elevated γ-GTP levels; this trend is consistent with previously reported trends [4, 15]. A study investigating dose-dependent effects of riluzole has suggested that hepatotoxicity reflects metabolic toxicity of riluzole [15, 17].

Fig. 1 (a) Chest X-ray and CT radiography of the 61-year-old man of IP show consolidation in bilateral lungs, dominantly in the lower and right side (arrows). (b) On the 24th day after treatment with oral PSL, the consolidations are improved. R: right
In this study, all cases with elevated liver enzymes that discontinued riluzole presented a history of medication for diabetes or hyperlipidemia (Tables 2 and 3); this may reflect increased metabolic ability. In addition, in some cases, biochemical analyses before riluzole administration revealed elevated γ-GTP; this also suggests that metabolic ability before medication is important. Since biochemical analysis does not always indicate asthenia and symptoms sometimes resemble disease progression, repeated interviews to assess general fatigue would be useful for making decision to discontinue riluzole considering patient’s quality of life (QOL).

Although the incidence of riluzole-induced IP is 0.1% in Japan according to a pharmaceutical reference, the incidence rate in our study was much higher at 4.3%. Because ALS patients complain of dyspnea with disease progression, IP might be overlooked sometimes. The proposed mechanism underlying IP in riluzole-administered patients includes dosage-dependent cell-mediated allergy along with increased CD8-positive lymphocytes in bronchoalveolar lavage and DLST [5]. We speculate that IP in our cases was caused by riluzole-induced allergy. In case 2, prolonged history of smoking may have triggered IP. Therefore, conducting repeated interviews and chest X-rays, as required, are important to differentiate adverse events from disease progression.

A double-blind trial of riluzole has shown that AST levels increased after 42 to 267 days of treatment initiation [4]. A dose-ranging study of riluzole has reported that the median duration of AST increase was 51 days in the 100 mg-dosing group [15]. Some case reports have shown elevated liver enzymes after 3 weeks, 4 weeks, and 6 months of riluzole initiation [6, 17], while in some other case reports of IP, this duration was 3 weeks, 4 weeks, and 2 months [13, 20]. Based on a phase III clinical trial and drug-use survey performed for 18 months [15] and the abovementioned reports of adverse events occurring from 7 days to 9 months, we considered our follow-up period of a median of 15.5 months to be sufficiently long. Indeed, in our cases, all adverse events occurred within 6 months after riluzole initiation, suggesting that careful follow-up for the first 6 months after riluzole initiation is important. Despite a sufficiently long follow-up, this report was retrospective and duration of drug administration was variable. Further investigations including prospective data and cases with comparable starting points and follow-up periods are warranted. Moreover, a selection bias existed because of the single-center nature of this study, and studies including more patients from multiple centers are imperative.

All but three cases of IP, which required steroid treatment, showed improvement soon after drug discontinuation. Only one IP case not require steroid treatment was diagnosed as IP with ground glass opacity (GGO) on chest X-ray and represented a very early stage of the event. Although responses to steroids were good, the three IP cases could have been mild. Furthermore, the need for steroids could have been eliminated if patients had earlier detection, as in the GGO case.

Riluzole has been reported to be well tolerated for long periods of up to 7 years or more in the real-world setting [10, 14]. However, recurrent pancreatitis in two ALS patients associated with riluzole treatment has been reported recently [9]; both patients were diagnosed with pancreatitis within 3 months after riluzole initiation. Once again, these reports emphasize the importance of careful observation of adverse events in the first 6 months after riluzole administration.

Although survival benefits of riluzole are debatable, some reports have suggested early benefits such that riluzole induced partial normalization of cortical and peripheral axonal hyperexcitability in the early stage of ALS [11] or increased survival in the last clinical stage of ALS [10]. In the light of these reports, it is advisable to continue riluzole as long as possible unless QOL is affected by the adverse events. When QOL is affected due to adverse events, riluzole should be discontinued rather than tapering administration, which is supported by the fact that all but three cases of IP in this study showed improvement simply with riluzole discontinuation [7, 9, 14, 16].

IP could be treated and lethal in most cases. Therefore, all ALS patients should be carefully followed up through interviews after riluzole initiation, especially for the first 6 months. When patients complain of respiratory problems, such as dyspnea or dry cough, chest X-ray should be recommended.

Riluzole was discontinued in 20 ALS patients (20/92) in this study. Moreover, incidence of IP was higher in this study than that reported in past studies, and strategies to differentiate IP from disease progression are warranted. Finally, careful follow-up for the first 6 months after the initiation of riluzole treatment is crucial, including thorough interviews, chemical analyses, and chest X-ray, as required.

**Abbreviations**

- %VC: Percent vital capacity
- ALS: Amyotrophic lateral sclerosis
- ALT: Alanine aminotransferase
- AST: Aspartate aminotransferase
- CT: Computed tomography
- DLCO: Diffusing capacity of the lung carbon monoxide
- FEV1.0%: Forced expiratory volume percent in one second
- FTD: Frontotemporal dementia
- FVC: Forced vital capacity
- GGO: Ground glass opacity
- IQR: Interquartile range
- KL-6: Krebs von den Lungen-6
- LDH: Lactate dehydrogenase
- Lt.: Left
- N/R/O: Not ruled out
- Na+: Sodium
- PPI: Proton pump inhibitors
- PSL: Prednisolone
- QOL: Quality of life
- S/O: Suspected of
- SP: Surfactant proteins

**Acknowledgments**

We would like to thank all who are participating in treatment of ALS patients in our Tohoku regional community.
Funding
No funding was obtained for the preparation of this case report.

Availability of data and materials
The source data supporting our data are stored in the archive of our center and are contained within the manuscript. The datasets used and/or analysed during the current study are from the corresponding author on reasonable request.

Authors’ contributions
All authors were involved in the clinical care of the patient. KH and TY were primary physician of the two patients in case reports. SN made substantial contributions to conception and design. KM and KY collected the clinical data. I-SA analyzed data and drafted the manuscript. IR, KJ, SN and WH helped interpreting the data, gave input into the discussion and participated in the conception and design of the report. AM gave final approval of the version to be published. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The study was submitted to and approved by the Ethics Committee of Tohoku University Graduate School of Medicine (2010–253, 2017–1-005). Consent to participate was directly provided by patients or their families.

Consent for publication
The written consents for publication were obtained from patients, including two individuals for case reports, or their families.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 29 September 2018 Accepted: 11 April 2019
Published online: 27 April 2019

References
1. Bellingham MC. A review of the neural mechanisms of action and clinical efficiency of Riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? CNS Neurosci Ther. 2011;17(1):4–31.
2. Bensimon G, A D. The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis. Expert Opinion Drug Saf. Nov. 2004;3(6): S25–S34.
3. Bensimon G, Lacomblez L, Dekumeau JC, Bejuit R, Truffinet P, Meininger V, Riluzole/ALS Study Group II. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol. 2002;249(5):609–15.
4. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole study group. N Engl J Med. 1994; 330(9):585–91.
5. Camus P, Fanton A, Bonnaind P, Camus C, Foucher P. Intestinal lung disease induced by drugs and radiation. Respiration; International Review of Thoracic Diseases. n.d.;71(4):301–26.
6. Castells U, Gámez J, Cervera C, J G. Icteric toxic hepatitis associated with riluzole outcome of raising blood pressure in patients with penetrating trunk. Lancet. 1998;351:1648.
7. Cetin H, Rath J, Füzi J, Reichardt B, Fülöp G, Koppi S, et al. Epidemiology of amyotrophic lateral sclerosis and effect of riluzole on disease course. Neuroepidemiology. 2015;44(6):15–19.
8. Chien L, Liu X, Tang L, Zhang N, Fan D. Long-term use of riluzole could improve the prognosis of sporadic amyotrophic lateral sclerosis patients: A real-world cohort study in China. Front Aging Neurosci. 2018;8(OC):1–8.
9. Falcão de Campos C, de Carvalho M. Riluzole-induced recurrent pancreatitis. J Clin Neurosci. 2017;45:153–4.
10. Fang T, Al Khleifat A, Meurey JH, Jones A, Leigh PN, Bensimon G, Al-Chalabi A. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: A retrospective analysis of data from a dose-ranging study. The Lancet Neurology. 2018;17(5):416–22.